Chemomab Therapeutics stock analysis
Want to see CMMB full AI Analyst Report?
Chemomab Therapeutics (CMMB) Stock Price & Analysis
CMMB Stock Chart & Stats
- Day’s Range
- $1.50 - $1.72
- 52-Week Range
- $0.92 - $2.99
- Previous Close
- $1.53
- Volume
- N/A
- Average Volume (3M)
- 49.79K
- Market Cap
- $11.74M
- Enterprise Value
- $6.28M
- Total Cash (Recent Filing)
- $6.69M
- Total Debt (Recent Filing)
- $0
- Price to Earnings (P/E)
- ―
- Beta
- 1.28
- Next Earnings
- Mar 10, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low leverage reduces fixed financial obligations and leaves less pressure from interest or debt repayment while the company advances clinical programs. This provides greater financial flexibility than a highly indebted structure, although it does not eliminate the need for future funding.
Improving Loss And Cash Burn Trend
The improvement in annual losses and cash burn suggests some expense discipline within the research-driven business. If maintained, this trend could extend the company’s funding runway and support continued development activity, even though operations remain far from self-funding.
Merger Transaction Advancing
Effectiveness of the registration statement marks substantive progress toward the planned Scipher Medicine merger and related transaction disclosures. Completion could reshape the company’s operating and financial platform, although closing remains dependent on the stated transaction requirements.
Bears Say
Pre-revenue Business Model
The absence of revenue means Chemomab has not yet demonstrated commercial traction or an internally funded operating model. Continued dependence on clinical progress before monetization leaves profitability and future financial strength reliant on successful development and eventual market adoption.
Persistent Cash Burn
Ongoing negative operating and free cash flow indicates that the company cannot currently fund research and corporate needs from operations. Continued external financing may be necessary, exposing the business to funding availability, dilution, and execution pressure over the next several quarters.
Declining Financial Base
The decline in assets and shareholders’ equity reflects continued operating losses and cash usage, reducing the financial cushion available for clinical development. Persistent erosion could increase dependence on capital raises and create greater dilution risk if the company remains unprofitable.
Chemomab Therapeutics News
CMMB FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
What is Chemomab Therapeutics’s market cap?
When is Chemomab Therapeutics’s upcoming earnings report date?
How were Chemomab Therapeutics’s earnings last quarter?
Is Chemomab Therapeutics overvalued?
Does Chemomab Therapeutics pay dividends?
What is Chemomab Therapeutics’s EPS estimate?
How many shares outstanding does Chemomab Therapeutics have?
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Chemomab Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Chemomab Therapeutics
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Adi Mor George
- Employees
- 12
- Website
- www.chemomab.com
- Address
- Building C, Tel Aviv-Yafo, TA, 6158101, IL
Chemomab Therapeutics (CMMB) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 3 | 10 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 7 | 0 | 5 |











